Hepatitis Therapeutics Market Growth & Trends
The global hepatitis therapeutics market size is expected to reach USD 20.84 billion by 2030, registering a CAGR of 3.7% during the forecast period. Few factors that are expected to drive the market over the forecast period include the rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.
Based on the duration for which the patient suffers, viral hepatitis is generally categorized into two types. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis. People with HIV infection & HCV-infected sexual partners, recipients of infected blood, patients who inject drugs & use intranasal drugs, and population groups who live in unhygienic conditions are at high risk of hepatitis.
Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, the majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.
Hepatitis Therapeutics Market Report Highlights
- Owing to the high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2023
- In 2023, North American region accounted for the majority of the revenue share, owing to high patient awareness levels and the presence of advanced healthcare infrastructure
- However, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 6.6% over the forecast period owing to rapidly increasing healthcare expenditure.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hepatitis Therapeutics Market Variables, Trends, & Scope
Chapter 4. Hepatitis Therapeutics Market: Disease Estimates & Trend Analysis
Chapter 5. Hepatitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
Chapter 6. Hepatitis Therapeutics Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Zydus Group
- GSK plc.
- AbbVie Inc.
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Lupin
- Cipla
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 16.27 Billion |
| Forecasted Market Value ( USD | $ 20.84 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
